Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks

Stock Research Monitor: PETX, BCRX, and BDSI

LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX). These stocks are part of the Biotechnology industry, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Aratana Therapeutics

Leawood, Kansas headquartered Aratana Therapeutics Inc.'s shares gained 1.47%, closing Wednesday's trading session at $5.54. The stock recorded a trading volume of 260,980 shares. The Company's shares have advanced 6.95% in the last month and 30.05% over the previous three months. The stock is trading 16.38% above its 50-day moving average and 2.41% above its 200-day moving average. Additionally, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the US and Belgium, have a Relative Strength Index (RSI) of 70.33.

On May 03rd, 2018, Aratana Therapeutics announced its Q1 2018 financial results. Total net revenues for Q1 2018 were $4.0 million, net loss was $8.5 million, and cost of product sales totaled $0.5 million. As of March 31st, 2018, the Company had approximately $67.3 million in cash, cash equivalents, restricted cash and short-term investments, which include net proceeds in the quarter from its at-the-market sales agreement of approximately $15.5 million. Get the full research report on PETX for free by clicking below at:

www.wallstequities.com/registration/?symbol=PETX

BioCryst Pharmaceuticals

On Wednesday, shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. recorded a trading volume of 852,517 shares, which was above their three months average volume of 822,230 shares. The stock rose 1.18%, ending the day at $5.98. The Company's shares have advanced 15.44% in the past month, 17.03% in the previous three months, and 2.93% over the past year. The stock is trading above its 50-day and 200-day moving averages by 16.44% and 19.77%, respectively. Furthermore, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 64.47.

On May 01st, 2018, BioCryst Pharma announced that the European Medicines Agency has approved peramivir with the brand name of ALPIVAB, a single intravenous infusion for the treatment of uncomplicated influenza in adults and children from the age of two years. The approval of ALPIVAB under the centralized licensing procedure provides marketing authorization for all 28-member states of the European Union, Norway, and Iceland. BCRX's complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=BCRX

BioDelivery Sciences International

Raleigh, North Carolina headquartered BioDelivery Sciences International Inc.'s stock finished the day flat at $1.95 with a total trading volume of 153,699 shares. The stock is trading below their 50-day moving average by 6.18%. Shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 48.84.

On May 07th, 2018, BioDelivery Sciences International announced that Herm Cukier has been appointed CEO and a member of the Company's Board of Directors, effective May 08th, 2018. Former President and CEO, Dr. Mark A. Sirgo, will continue his role as Vice Chairman of the Board and, along with current President Scott Plesha, will work closely with Mr. Cukier in the transition of responsibilities. Register for your free research report on BDSI at:

www.wallstequities.com/registration/?symbol=BDSI

BioLine Rx

Shares in Modi'in, Israel headquartered BioLine Rx Ltd ended yesterday's session 8.28% higher at $0.89. The stock recorded a trading volume of 1.36 million shares, which was above its three months average volume of 219,680 shares. The Company's shares have advanced 3.44% in the last month and 5.68% over the past year. The stock is trading 0.70% above its 50-day moving average. Moreover, shares of BioLine Rx, which focuses on oncology and immunology, have an RSI of 58.23. Wall St. Equities' downloadable research report on BLRX available at:

www.wallstequities.com/registration/?symbol=BLRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities